Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | DRD1 | P21728 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 3/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | SMO | Q99835 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22472894 | 0.90 | LMNA (0.36) | LMNACHRM2ADRA2ACYP2D6TSHR | |
| SCHEMBL17101358 | 0.89 | CHRM1 (0.42) | LMNACHRM2ADRA2ACYP2D6TSHR | |
| SCHEMBL21597936 | 0.88 | CHRM1 (0.35) | LMNACHRM2ADRA2ACYP2D6TSHR | |
| SCHEMBL17101373 | 0.87 | CHRM1 (0.40) | LMNACHRM2ADRA2ACYP2D6TSHR | |
| SCHEMBL17101520 | 0.85 | CHRM1 (0.43) | LMNACHRM2MAPTPOLBCHRM1 | |
| SCHEMBL17101445 | 0.81 | LMNA (0.34) | LMNACHRM2ADRA2ACYP2D6TSHR | |
| SCHEMBL20384955 | 0.81 | POLB (0.35) | LMNACHRM2ADRA2ACYP2D6TSHR | |
| SCHEMBL22472870 | 0.80 | CYP11B1 (0.35) | LMNACHRM2POLBTP53L3MBTL1 | |
| SCHEMBL22472893 | 0.79 | CHRM1 (0.31) | LMNAPOLBTP53L3MBTL1CHRM1 | |
| SCHEMBL17101302 | 0.78 | CHRM1 (0.34) | LMNACHRM2ADRA2ACYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10787447-B2 | Pharmaceutical compounds | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10787447-B2 | Pharmaceutical compounds | CHRM1, CHRM2, CHRM4 | LMNA 3439/4885CHRM2 2/4885ADRA2A 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.